Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Peripheral Stem Transplantation in Treating Patients With Refractory or Relapsed Lymphoma

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II, Phase I Treatment Active 65 and under NCI FHCRC-1409.00 NCI-G00-1776, NCT00005803

Objectives

Primary

1. Assess engraftment of HLA-identical peripheral blood stem cell (PBSC) allografts given after conditioning with total body irradiation and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil in patients with refractory or relapsed lymphoma treated with initial autologous PBSC transplantation.
2. Determine nonrelapse mortality at day 100 in patients treated with this regimen.

Secondary

1. Determine disease-free and overall survival of patients treated with this regimen.

Entry Criteria

Disease Characteristics:

• Primary Hodgkin's or non-Hodgkin's lymphoma
  • Refractory or relapsed disease after standard chemotherapy
  • At high-risk of relapse with conventional autografting
  • Tumor detectable by radiograph or bone marrow biopsy



• HLA genotypically- or phynotypically-identical related donor available
  • Not identical twin
  • Age 12 and over
  • Able to donate peripheral blood stem cells (PBSC) and lymphocytes

Prior/Concurrent Therapy:

Biologic therapy:

• No prior autologous stem cell transplantation using CD34-positive PBSC
• No concurrent growth factors during mycophenolate mofetil administration

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 3 months since prior radiotherapy to the mediastinum

Surgery:

• Not specified

Patient Characteristics:

Age:

• 65 and under

Performance status:

• Karnofsky 60-100%

Life expectancy:

• At least 3 months
• No life expectancy severely limited by disease other than lymphoma

Hematopoietic:

• Not specified

Hepatic:

• Not at high risk for veno-occlusive disease of the liver
• Bilirubin no greater than 2.0 mg/dL
• SGOT or SGPT no greater than 2 times normal

Renal:

• Creatinine no greater than 2.0 mg/dL
• Creatinine clearance at least 50 mL/min

Cardiovascular:

• Cardiac ejection fraction at least 45% by MUGA or cardiac echo (for patients with a history of cardiac disease or anthracycline use)
• No poorly controlled hypertension

Pulmonary:

• DLCO at least 50% of predicted

Other:

• HIV negative
• Not pregnant
• Fertile patients must use effective contraception during and for 1 year after study participation

Expected Enrollment

A total of 40 patients will be accrued for this study within 4 years.

Outcomes

Engraftment of HLA-identical peripheral blood stem cell allografts
Non-relapse mortality at day 100

Outline

This is a multicenter study. Patients are stratified according to response to prior chemotherapy (sensitive vs resistant).

Patients who do not have autologous peripheral blood stem cells (PBSC) stored receive mobilization on another protocol, then have PBSC collected and stored. Patients then proceed to conditioning and transplantation.

Patients may receive one of two conditioning regimens.

• Regimen 1: Patients receive cyclophosphamide IV on days -6 and -5 followed by total body irradiation (TBI) twice a day on days -3 to -1.



• Regimen 2: Patients receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours and cytarabine IV over 3 hours twice a day on days -6 to -3, and melphalan IV over 30 minutes on day -2.

After completion of conditioning therapy, all patients undergo reinfusion of autologous PBSC on day 0. Some patients may receive involved field irradiation to bulky disease after autologous PBSC reinfusion and before nonmyeloablative allograft.

Within 40-120 days after autologous PBSC transplantation, patients proceed to nonmyeloablative allograft. Cyclosporine administered orally twice daily on days -3 to 56, then tapered based on disease risk. TBI is administered on day 0 followed by allogeneic PBSC infusion. Patients also receive oral mycophenolate mofetil twice a day beginning on day 0 and continuing until day 27.

Based on day 56 disease status, patients may receive donor lymphocyte infusion (DLI) if there is evidence of disease progression and no evidence of graft-vs-host disease. DLI may be repeated every 65 days for up to 4 doses.

Patients are followed weekly for 3 months, at 4 and 6 months, every 6 months for 2 years, and then annually until 5 years after transplantation.

Trial Contact Information

Trial Lead Organizations

Fred Hutchinson Cancer Research Center

David Maloney, MD, PhD, Protocol chair		Ph: 206-667-5616 Email: dmaloney@fhcrc.org

U.S.A.
Texas
	Dallas
	Charles A. Sammons Cancer Center
		Edward Agura, MD	Ph:  214-820-1800
			Email: edwarda@baylorhealth.edu
Utah
	Salt Lake City
	Huntsman Cancer Institute at University of Utah
		Michael Pulsipher, MD	Ph:  801-585-3229
			Email: michael.pulsipher@hsc.utah.edu
Washington
	Seattle
	Fred Hutchinson Cancer Research Center
		David Maloney, MD, PhD	Ph:  206-667-5616
			Email: dmaloney@fhcrc.org
	Seattle Cancer Care Alliance
		Clinical Trials Office - Seattle Cancer Care Alliance	Ph:  800-804-8824
	Veterans Affairs Medical Center - Seattle
		William Schubach, MD	Ph:  206-764-2265 800-329-8387
Germany
	Leipzig
	Universitaet Leipzig
		Dietger Niederwieser, MD	Ph:  49-341-971-3050
			Email: dietger@medizin.uni_leipzig.de

Registry Information
Official Title		A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi Center Trial
Trial Start Date		1999-09-02
Trial Completion Date		2010-09-02 (estimated)
Registered in ClinicalTrials.gov		NCT00005803
Date Submitted to PDQ		2000-03-08
Information Last Verified		2008-04-06
NCI Grant/Contract Number		CA15704, CA78902

Back to Top